AiCure is combining a decade’s worth of research into real-world patient behavior with an artificial intelligence platform to optimize patient adherence to treatments in clinical trials. Lack of patient compliance to long-term treatments can lead...

INDICATION: Adenocarcinoma; brain cancer; lung cancer; neuroendocrine tumors Cell culture studies identified a nicotonic acetylcholine receptor α7 (CHRNA7) antagonist that could help treat glioblastoma, lung adenocarcinoma and neuroblastoma. Chemical synthesis and cell-based testing of structural...

Stanford University professors launched Katexco Pharmaceuticals Corp. (Toronto, Ontario) to develop therapies that target endocannabinoid and nicotine receptors to treat inflammatory diseases. Katexco has exclusively licensed IP from the university. The IP was generated by...

Bionomics Ltd. (ASX:BNO; OTCQX;BNOEF) discontinued development of BNC210 to treat posttraumatic stress disorder (PTSD) after the compound missed the primary endpoint in the Phase II RESTORE trial in the indication. Twice-daily oral BNC210 did not...

Cough company Attenua Inc. (Mountain View, Calif.) raised $35 million in a series A round on April 30 in a series A round led by new investor Omega Funds. New investors Abingworth, OrbiMed Advisors and...

Attenua Inc. (Mountain View, Calif.) raised $35 million in a series A round led by new investor Omega Funds. New investors Abingworth, OrbiMed Advisors and Redmile Group also participated. Attenua plans to start Phase II...

Bionomics will receive a $10 milestone payment from Merck under a 2014 deal granting the pharma exclusive, worldwide development and commercialization rights to Bionomics’ BNC375 program, which targets cognitive dysfunction associated with Alzheimer’s disease and...

INDICATION: Asthma Cell culture and mouse studies suggest CHRNA7 agonists could help treat allergic asthma. In a mouse model of airway hyperresponsiveness, intranasal administration of a CHRNA7 agonist tool compound decreased airway resistance and dynamic...

Top-line data from the double-blind, placebo- and lorazepam-controlled, 4-way crossover, U.K. Phase II BNC210.006 trial in 24 patients with untreated GAD showed that a single oral dose of 300 mg BNC210 met the co-primary endpoints...

Catalyst will sell TC-5619, TC-6987 and TC-6683 (AZD1446) to Attenua for $1 million up front and for up to $105 million in milestones, plus royalties. Catalyst gained the products when it merged with Targacept Inc....